Series B Funded Startups in Belgium
These 20 Series B rounds in Belgium span 2021-04-01 (AppTweak) through 2025-07-01 (Animab), with the most recent cluster landing in mid-2024 to mid-2025.
These 20 Series B rounds in Belgium span 2021-04-01 (AppTweak) through 2025-07-01 (Animab), with the most recent cluster landing in mid-2024 to mid-2025. The size distribution is sharply uneven: Precirix’s $88M (2022-03-16) is the largest disclosed round and sits well above the rest, which include a small set in the tens of millions (e.g., Confo Therapeutics $65M on 2024-07-26, Nobi $37M on 2025-01-28) but otherwise fall closer to the $10M–$25M band.
Sector-wise, biotechnology dominates: it appears in 6 of the 20 rows (Animab, Confo Therapeutics, Novadip Biosciences, eTheRNA immunotherapies, AgomAb Therapeutics, Precirix). Geography is concentrated in Brussels and Antwerp-area metros: Brussels-based rounds include Fyteko ($14M, 2025-02-13), Confo Therapeutics ($65M, 2024-07-26), Dust Mobile ($12M, 2022-11-23), eTheRNA immunotherapies (2022-08-23, $39M), AgomAb Therapeutics (2022-07-13, $39M), Precirix (2022-03-16, $88M), Sortlist ($13M, 2021-09-15), Qover ($25M, 2021-04-27), and AppTweak ($22M, 2021-04-01). By contrast, the smallest disclosed amount is BOTALYS at $690K (2023-05-22), an outlier relative to the predominantly mid-figure millions elsewhere.
Most recent rounds
20 shownRelated listings
Frequently asked
What’s the largest disclosed Series B round here, and how does it compare to the rest of the table?
Precirix’s $88M (2022-03-16) is the top disclosed amount and it dwarfs the next-highest figures in the list, such as Confo Therapeutics’ $65M (2024-07-26) and Nobi’s $37M (2025-01-28). Most other disclosed rounds cluster below that top tier, including multiple $20M–$25M rounds (e.g., Gorilla $25M on 2024-06-12; intigriti $23M on 2022-04-26).
Are there any notable outliers on the low end of disclosed amounts?
BOTALYS stands out as the smallest disclosed round at $690K on 2023-05-22, far below the rest of the disclosed amounts that mostly sit in the $9M–$39M range (e.g., MobieTrain $9M on 2022-10-27; Rejuvenate Biomed $18M on 2021-10-12).
Do any cities appear over-represented among the Brussels/Antwerp metros in this Series B set?
Brussels-area locations show up repeatedly, including multiple rounds in Brussels/Brussels Hoofdstedelijk Gewest such as Fyteko $14M (2025-02-13), Confo Therapeutics $65M (2024-07-26), Dust Mobile $12M (2022-11-23), eTheRNA immunotherapies $39M (2022-08-23), Precirix $88M (2022-03-16), Qover $25M (2021-04-27), and AppTweak $22M (2021-04-01). Antwerp-area also appears as a frequent second hub (e.g., Nobi in Antwerpen $37M on 2025-01-28; intigriti $23M on 2022-04-26; Rombit $25M on 2022-02-16).
Which sector dominates this list, and how concentrated is it?
Biotechnology is the clear concentration, appearing in 6 of the 20 rows: Animab ($12M, 2025-07-01), Confo Therapeutics ($65M, 2024-07-26), Novadip Biosciences ($23M, 2022-11-03), eTheRNA immunotherapies ($39M, 2022-08-23), AgomAb Therapeutics ($39M, 2022-07-13), and Precirix ($88M, 2022-03-16). Other categories are present but with fewer entries each (e.g., Information Technology in 4 rows, Advertising in 3).
What does the timing look like—are there recent entries within a defined window?
Within the most recent ~90 days from the table’s latest date (2025-07-01), there is one additional entry in that window: Animab closes on 2025-07-01, with the preceding Series B rounds dated 2025-02-13 (Fyteko) and 2025-01-28 (Nobi). More broadly, the table shows a run of activity from June 2024 to July 2025, including TechWolf ($43M, 2024-06-24), Gorilla ($25M, 2024-06-12), Nobi ($37M, 2025-01-28), and Animab ($12M, 2025-07-01).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.